Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubidium-82 chloride is a **radiopharmaceutical diagnostic agent** primarily used in **Positron Emission Tomography (PET) imaging** of the myocardium, under rest or pharmacologic stress, to evaluate **regional myocardial perfusion** in adult patients with suspected or known **coronary artery disease**[1][2][3][5]. The compound consists of the radioactive isotope rubidium-82 (half-life 75 seconds), produced onsite from a strontium-82 generator and administered intravenously. Biologically, Rb-82 acts as a **potassium analog** due to its similar ionic radius, allowing it to be rapidly taken up by myocardial cells in proportion to blood flow, thus enabling perfusion imaging[2][4]. In areas of infarction or ischemia, reduced uptake provides diagnostic information about myocardial viability[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rubidium-82 chloride.